Ove Almkvist
Affiliations: | NVS | Karolinska Institute, Stockholm, Sweden |
Google:
"Ove Almkvist"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Almkvist O, Larsson M, Graff C. (2023) Odor Identification Across Time in Mutation Carriers and Non-Carriers in Autosomal-Dominant Alzheimer's Disease. Journal of Alzheimer's Disease : Jad |
| Almkvist O, Nordberg A. (2023) A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer's disease. Alzheimer's Research & Therapy. 15: 89 |
| Almkvist O, Graff C. (2022) Practice effects in cognitive assessments three years later in non-carriers but not in symptom-free mutation carriers of autosomal-dominant Alzheimer's disease: Exemplifying procedural learning and memory? Frontiers in Aging Neuroscience. 14: 905329 |
| Almkvist O, Johansson C, Laffita-Mesa J, et al. (2022) APOE ε4 influences cognitive decline positively in APP and negatively in PSEN1 mutation carriers with autosomal-dominant Alzheimer's disease. European Journal of Neurology |
| Almkvist O, Graff C. (2021) The ε4 Allele Affects Cognitive Functions Differently in Carriers of Mutations Compared to Carriers of Mutations in Autosomal-Dominant Alzheimer's Disease. Genes. 12 |
| Almkvist O, Brüggen K, Nordberg A. (2021) Subcortical and Cortical Regions of Amyloid-β Pathology Measured by 11C-PiB PET Are Differentially Associated with Cognitive Functions and Stages of Disease in Memory Clinic Patients. Journal of Alzheimer's Disease : Jad |
| Thordardottir S, Almkvist O, Johansson C, et al. (2020) Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer's Disease: A Pilot Study. Journal of Alzheimer's Disease : Jad |
| Vilaplana E, Rodriguez-Vieitez E, Ferreira D, et al. (2020) Cortical microstructural correlates of astrocytosis in autosomal dominant Alzheimer disease. Neurology |
| Karami A, Eriksdotter M, Kadir A, et al. (2019) CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer's Disease. Frontiers in Molecular Neuroscience. 12: 239 |
| Almkvist O, Rodriguez-Vieitez E, Thordardottir S, et al. (2019) Longitudinal cognitive decline in autosomal-dominant Alzheimer's disease varies with mutations in APP and PSEN1 genes. Neurobiology of Aging. 82: 40-47 |